Teva Loses Exclusivity On Generic Pravachol; Earlier Court Case Was Trigger
Executive Summary
Teva has nine months to resolve questions surrounding its first-to-file rights for generic pravastatin before the expiration of Bristol-Myers Squibb's exclusivity for Pravachol in April 2006
You may also be interested in...
Pravachol Exclusivity Ruling Adds Uncertainty For ANDA Filers, Counsel Says
A court decision reinstating Teva's generic exclusivity rights for Pravachol will make it more difficult for ANDA filers to predict when a dismissed declaratory judgment action could trigger 180-day exclusivity, FDA Associate Chief Counsel Elizabeth Dickinson said Oct. 26
Pravachol Exclusivity Ruling Adds Uncertainty For ANDA Filers, Counsel Says
A court decision reinstating Teva's generic exclusivity rights for Pravachol will make it more difficult for ANDA filers to predict when a dismissed declaratory judgment action could trigger 180-day exclusivity, FDA Associate Chief Counsel Elizabeth Dickinson said Oct. 26
Generic Exclusivity Forfeiture Provisions Put FDA In “Hot Seat”
FDA is grappling with how to define triggers for forfeiture of generic exclusivity as it develops regulations to implement changes in Hatch/Waxman created by the Medicare Modernization Act of 2003